GET THE PREMIUM SUBSCRIPTION FREE FOR 14 DAYS!

Cellectis S.A. Company Profile

8, rue de la Croix Jarry

Paris 75013

33 1 81 69 16 00

www.cellectis.com

Industry: Biotechnology

Sector: Healthcare

Cellectis S.A.

Description

Cellectis S.A., a gene-editing company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART38 for T-cell ALL and MM; and UCART22 for ALL. It has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; and The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various types of liquid tumors. Cellectis S.A. was founded in 1999 and is based in Paris, France.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE